Elżbieta Pajtasz-Piasecka

Prof. Dr. Elżbieta Pajtasz-Piasecka

orcid

Research Focus & Metrics

Academic Career Length

41Years (1986-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 August 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
PMPaulina Miernikiewicz
Paulina Miernikiewicz
KDKrystyna Dąbrowska
Krystyna Dąbrowska
APAgnieszka Piotrowicz
Agnieszka Piotrowicz
BOBarbara Owczarek
Barbara Owczarek
JWJustyna Wojas-Turek
Justyna Wojas-Turek
AGAndrzej Górski
Andrzej Górski
Viruses are potent activators of the signal pathways leading to increased cytokine or ROS production. The effects exerted on the immune system are usually mediated by viral proteins. Complementary to the progress in phage therapy practice, advancement of knowledge about the influence of bacteriophages on mammalian immunity is necessary. Particularly, the potential ability of phage proteins to act like other viral stimulators of the immune system may have strong practical implications for the safety and efficacy of bacteriophage therapy. Here we present studies on the effect of T4 phage and its head proteins on production of inflammatory mediators and inflammation-related factors: IL-1α, IL-1β, IL-2, IL-6, IL-10, IL-12 p40/p70, IFN-γ, TNF-α, MCP-1, MIG, RANTES, GCSF, GM-CSF and reactive oxygen species (ROS). Plasma cytokine profiles in an in vivo mouse model and in human blood cells treated with gp23*, gp24*, Hoc and Soc were evaluated by cytokine antibody arrays. Cytokine production and expression of CD40, CD80, CD86 and MHC class II molecules were also investigated in mouse bone marrow-derived dendritic cells treated with whole T4 phage particle or the same capsid proteins. The influence of T4 and gp23*, gp24*, Hoc and Soc on reactive oxygen species generation was examined in blood cells using luminol-dependent chemiluminescence assay. In all performed assays, the T4 bacteriophage and its capsid proteins gp23*, gp24*, Hoc and Soc did not affect production of inflammatory-related cytokines or ROS. These observations are of importance for any medical or veterinary application of bacteriophages.

1 August 2023 in International Journal of Nanomedicine
Verified
Journal Article
Open access
PDF file
AWAnna Wróblewska
Anna Wróblewska
ASAgnieszka Szczygieł
Agnieszka Szczygieł
BSBożena Szermer-Olearnik
Bożena Szermer-Olearnik
EPElżbieta Pajtasz-Piasecka
Elżbieta Pajtasz-Piasecka
Macrophages play a critical role in the immune response due to their ability to recognize and remove pathogens, as well as present antigens, which are involved in inflammation, but they are also one of the most abundant immune cell populations present in the tumor microenvironment. In recent years, macrophages have become promising cellular carriers for drug and nanoparticle delivery to the tumor microenvironment, mainly due to their natural properties such as biocompatibility, degradability, lack of immunogenicity, long half-life in circulation, crossing biological barriers, and the possibility of migration and accumulation at a site of inflammation such as a tumor. For the effectiveness of this therapeutic strategy, known as “Trojan horse”, it is important that the nanoparticles engulfed by macrophages do not affect their proper functioning. In our review, we discussed how the size, shape, chemical and mechanical properties of nanoparticles influence their internalization by macrophages. In addition, we described the promising research utilizing macrophages, their cell membranes and macrophage-derived exosomes as drug carriers in anticancer therapy. As a prospect of the wider use of this therapeutic strategy, we postulate its future application in boron delivery to the tumor environment in boron neutron capture therapy.

1 December 2014 in International Immunopharmacology
Verified
Journal Article
Closed access
BOBeata Orzechowska
Beata Orzechowska
RCRadosław Chaber
Radosław Chaber
AWA. Wiśniewska
A. Wiśniewska
EPElżbieta Pajtasz-Piasecka
Elżbieta Pajtasz-Piasecka
BJB. Jatczak
B. Jatczak
ZBZ. Błach-Olszewska
Z. Błach-Olszewska

13 February 2019 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
JRJoanna Rossowska
Joanna Rossowska
NANatalia Anger
Natalia Anger
KWKatarzyna Wegierek
Katarzyna Wegierek
ASAgnieszka Szczygieł
Agnieszka Szczygieł
JMJagoda Mierzejewska
Jagoda Mierzejewska
EPElżbieta Pajtasz-Piasecka
Elżbieta Pajtasz-Piasecka
Recent developments demonstrate that tumor-derived extracellular vesicles (EVs) could become a highly effective tool for delivery of antitumor factors. The main objective of the study was to determine whether EVs secreted by MC38 colon carcinoma cells genetically engineered for overproduction of interleukin (IL-)12 and/or shRNA targeting TGF-β1 are effectively loaded with these molecules and whether the obtained EVs could be an efficient tool for antitumor therapy. Fractions of EVs released by genetically modified MC38 cells [both modified tumor-derived exosomes (mTEx) and modified microvesicles (mTMv)] and those released by unmodified, wild-type MC38 cells were characterized in terms of loading efficacy, using real-time PCR and ELISA, as well as their antitumor potential. In order to examine the therapeutic potential of mTEx, they were applied in the form of sole treatment as well as in combination with dendritic cell (DC)-based vaccines stimulated with mTMv in the therapy of mice with subcutaneously growing MC38 tumors. The results demonstrated that genetic modification of wild-type MC38 tumor cells is an effective method of loading the molecules of interest into extracellular vesicles secreted by the cells (both TEx and TMv). The results also showed that mTEx secreted by cells engineered for overproduction of IL-12 and/or shRNA for TGF-β1 are able to induce tumor growth inhibition as opposed to TEx from unmodified MC38 cells. Additionally, antitumor therapy composed of mTEx (especially those deprived of TGF-β1) and DC-based vaccines allowed for regeneration of antitumor immunity and induction of the systemic Th1 response responsible for the sustained effect of the therapy. In conclusion, tumor-derived exosomes loaded with IL-12 and/or deprived of TGF-β1 could become an efficient adjuvant supporting induction of a specific antitumor response in both immuno- and chemotherapeutic schemes of treatment.

3 January 2014 in Journal of Leukocyte Biology
Verified
Journal Article
Closed access
PDF file
RMRomana Mikyšková
Romana Mikyšková
MIMarie Indrová
Marie Indrová
VVVeronika Vlková
Veronika Vlková
JBJana Bieblová
Jana Bieblová
JŠJana Šímová
Jana Šímová
MRMilan Reiniš
Milan Reiniš
MDSCs represent one of the key players mediating immunosuppression. These cells accumulate in the TME, lymphoid organs, and blood during tumor growth. Their mobilization was also reported after CY therapy. DNMTi 5AC has been intensively studied as an antitumor agent. In this study, we examined, using two different murine tumor models, the modulatory effects of 5AC on TU-MDSCs and CY-MDSCs tumor growth and CY therapy. Indeed, the percentage of MDSCs in the TME and spleens of 5AC-treated mice bearing TRAMP-C2 or TC-1/A9 tumors was found decreased. The changes in the MDSC percentage were accompanied by a decrease in the Arg-1 gene expression, both in the TME and spleens. CY treatment of the tumors resulted in additional MDSC accumulation in the TME and spleens. This accumulation was subsequently inhibited by 5AC treatment. A combination of CY with 5AC led to the highest tumor growth inhibition. Furthermore, in vitro cultivation of spleen MDSCs in the presence of 5AC reduced the percentage of MDSCs. This reduction was associated with an increased percentage of CD11c+ and CD86+/MHCII+ cells. The observed modulatory effect on MDSCs correlated with a reduction of the Arg-1 gene expression, VEGF production, and loss of suppressive capacity. Similar, albeit weaker effects were observed when MDSCs from the spleens of tumor-bearing animals were cultivated with 5AC. Our findings indicate that beside the direct antitumor effect, 5AC can reduce the percentage of MDSCs accumulating in the TME and spleens during tumor growth and CY chemotherapy, which can be beneficial for the outcome of cancer therapy.

1 February 2008 in Immunology Letters
Verified
Journal Article
Closed access
EPElżbieta Pajtasz-Piasecka
Elżbieta Pajtasz-Piasecka
JRJoanna Rossowska
Joanna Rossowska
DDDanuta Duś
Danuta Duś
BWBeata Weber-Dąbrowska
Beata Weber-Dąbrowska
AZAgnieszka Zabłocka
Agnieszka Zabłocka
AGAndrzej Górski
Andrzej Górski